Semaglutide Dosage: Doses Studied, Units and Chart
What doses of Semaglutide have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 18 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- approximately 1 week
- subcutaneous, in people · FDA label (Ozempic)
- Vial sizes sold
- 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Dosing on the FDA label
Quoted from the approved product label. It applies to the approved product used as prescribed, not to compounded or research-chemical versions.
- Starting dose: 0.25 mg subcutaneously once weekly for 4 weeks · FDA label (Ozempic)
- Escalation to 0.5 mg after 4 weeks · FDA label (Ozempic)
- Maximum recommended dosage: 2 mg once weekly · FDA label (Ozempic)
- Starting dose: 0.25 mg subcutaneously once weekly · FDA label (Wegovy)
- Escalation schedule (0.25, 0.5, 1, 1.7 mg at 4-week steps) · FDA label (Wegovy)
- Maintenance dosage for weight reduction in adults · FDA label (Wegovy)
- Maximum dosage · FDA label (Wegovy)
- Starting dose: 3 mg orally once daily (not effective for glycemic control) · FDA label (Rybelsus, Ozempic tablets)
- Escalation to 7 mg on days 31 to 60 · FDA label (Rybelsus, Ozempic tablets)
- Escalation to 14 mg if additional glycemic control is needed · FDA label (Rybelsus, Ozempic tablets)
- Administration: empty stomach with up to 4 ounces of water · FDA label (Rybelsus, Ozempic tablets)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 14 mg (flexible dose) | once-daily · oral · up to 156 weeks | Human RCTn = 3808 | Lancet 2026, PMID 41865758 |
| 2.4 mg | once-weekly · subcutaneous · 240 weeks (interim at week 72) | Human RCTn = 1197 | The New England journal of medicine 2025, PMID 40305708 |
| 25 mg | once daily · oral · 71-week trial, primary end point at week 64 | Human RCTn = 307 | The New England journal of medicine 2025, PMID 40934115 |
| 7·2 mg vs 2·4 mg | once-weekly · subcutaneous · 72 weeks | Human RCTn = 1407 | The lancet. Diabetes & endocrinology 2025, PMID 40961952 |
| 2.4 mg | per week · 24 weeks | Human RCTn = 101 | Nature medicine 2025, PMID 39455729 |
| 1.0 mg | once-weekly · subcutaneous · 26 weeks (primary), 52 weeks (MRI) | Human RCTn = 101 | American heart journal 2025, PMID 40345413 |
| 1.0 mg | weekly · subcutaneous · median follow-up 3.4 years | Human RCTn = 3533 | The New England journal of medicine 2024, PMID 38785209 |
| 2.4 mg | once-weekly · subcutaneous · 68 weeks | Human RCTn = 407 | The New England journal of medicine 2024, PMID 39476339 |
| 2.4 mg | once-weekly · subcutaneous · mean follow-up 39.8 months | Human RCTn = 17604 | The New England journal of medicine 2023, PMID 37952131 |
| 2.4 mg | once-weekly · 52 weeks | Human RCTn = 529 | The New England journal of medicine 2023, PMID 37622681 |
| semaglutide 2.4 mg vs liraglutide 3.0 mg | once-weekly (semaglutide); once-daily (liraglutide) · subcutaneous · 68 weeks | Human controlled trialn = 338 | JAMA 2022, PMID 35015037 |
| 2.4 mg | once weekly · subcutaneous · 68 weeks | Human RCTn = 1961 | The New England journal of medicine 2021, PMID 33567185 |
| 2.4 mg | once weekly · subcutaneous · 20-week run-in then 48 weeks | Human RCTn = 803 | JAMA 2021, PMID 33755728 |
| 2·4 mg or 1·0 mg | once a week · subcutaneous · 68 weeks | Human RCTn = 1210 | Lancet 2021, PMID 33667417 |
| 2.4 mg | once-weekly · subcutaneous · 68 weeks | Human RCTn = 611 | JAMA 2021, PMID 33625476 |
| 0.1, 0.2, or 0.4 mg | once-daily · subcutaneous · 72 weeks | Human RCTn = 320 | The New England journal of medicine 2021, PMID 33185364 |
| semaglutide 0·5 or 1·0 mg vs dulaglutide 0·75 or 1·5 mg | once a week · subcutaneous · 40 weeks | Human controlled trialn = 1201 | The lancet. Diabetes & endocrinology 2018, PMID 29397376 |
| 0.5 mg or 1.0 mg | once-weekly · 104 weeks | Human RCTn = 3297 | The New England journal of medicine 2016, PMID 27633186 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 0.25 mg
- 5 u
- 0.5 mg
- 10 u
- 1 mg
- 20 u
- 1.5 mg
- 30 u
- 2 mg
- 40 u
- 2.5 mg
- 50 u
Before anyone considers it
- Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus); research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
How many units is 1 mg of Semaglutide?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe. Use the calculator for other mixes.
Is Semaglutide FDA approved?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
More on Semaglutide
Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGFDA label (Wegovy), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (FDA label (Rybelsus, Ozempic tablets), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.The lancet. Diabetes & endocrinology · 2025PMID 40961952Accessed 2 Oct 2026
- 10Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
- 11Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
- 12Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
- 13Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.The New England journal of medicine · 2024PMID 39476339Accessed 2 Oct 2026
- 14Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
- 15Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2023PMID 37622681Accessed 2 Oct 2026
- 16Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA · 2022PMID 35015037Accessed 2 Oct 2026
- 17Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 18Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA · 2021PMID 33755728Accessed 2 Oct 2026
- 19Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet (London, England) · 2021PMID 33667417Accessed 2 Oct 2026
- 20Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.JAMA · 2021PMID 33625476Accessed 2 Oct 2026
- 21A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.The New England journal of medicine · 2021PMID 33185364Accessed 2 Oct 2026
- 22Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.The lancet. Diabetes & endocrinology · 2018PMID 29397376Accessed 2 Oct 2026
- 23Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026
Found an error? Report a correction.